Plasma-derived product · Immune activation · developed by ADMA Biologics
Asceniv is an intravenous immune globulin derived from human plasma. It provides passive immunotherapy by supplying immunoglobulins to patients with primary immune deficiency disorders.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01814800 | Phase 3 | Primary Immune Deficiency Disorder | Completed | ADMA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Primary Immune Deficiency Disorder
Updated Oct 3, 2026. Something wrong or missing? Report it on the ADMA page.
See ADMA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ADMA catalysts and pipeline →